BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 104 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $134,000 | -60.8% | 10,677 | -49.2% | 0.02% | -40.5% |
| Q1 2022 | $342,000 | -82.1% | 21,035 | -91.8% | 0.04% | -76.1% |
| Q4 2020 | $1,908,000 | +418.5% | 256,210 | +231.4% | 0.16% | +307.9% |
| Q2 2020 | $368,000 | +332.9% | 77,301 | +212.9% | 0.04% | +1166.7% |
| Q4 2019 | $85,000 | +3.7% | 24,704 | -14.7% | 0.00% | -25.0% |
| Q3 2019 | $82,000 | -57.3% | 28,949 | +21.6% | 0.00% | -60.0% |
| Q4 2018 | $192,000 | -55.1% | 23,800 | -68.2% | 0.01% | +11.1% |
| Q2 2018 | $428,000 | +46.1% | 74,800 | -27.9% | 0.01% | -35.7% |
| Q1 2016 | $293,000 | +35.0% | 103,800 | +443.5% | 0.01% | -12.5% |
| Q3 2015 | $217,000 | -15.9% | 19,100 | +10.4% | 0.02% | -59.0% |
| Q2 2015 | $258,000 | +113.2% | 17,300 | +50.4% | 0.04% | +550.0% |
| Q1 2014 | $121,000 | – | 11,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 7,637,700 | $77,675,000 | 7.44% |
| Burrage Capital Management LLC | 864,916 | $8,796,000 | 7.13% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,367,670 | $24,079,000 | 3.61% |
| HealthCor Management, L.P. | 4,886,440 | $49,695,000 | 1.76% |
| Ghost Tree Capital, LLC | 500,000 | $5,085,000 | 1.20% |
| Integral Health Asset Management, LLC | 400,000 | $4,068,000 | 1.16% |
| Lisanti Capital Growth, LLC | 472,520 | $4,806,000 | 0.62% |
| Parkman Healthcare Partners LLC | 244,680 | $2,488,000 | 0.58% |
| Baker Brothers Advisors | 12,710,818 | $129,269,000 | 0.56% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,605,380 | $26,497,000 | 0.56% |